Abraham, John (1993): «Scientific Standards and Institutional Interests: Carcinogenic Risk Assessment of Benoxaprofen in the UK and US», Social...
Abraham, John (1995): Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation, Londres: UCL y St Martins...
Abraham, John (2002): «The Pharmaceutical Industry as a Political Player», The Lancet, 360: 1498-1502.
Abraham, John (2007): «Drug Trials and Evidence Bases in International Regulatory Context», BioSocieties, 2: 41-56.
Abraham, John (2008): «Bias and Science in Knowledge Production: Implications for the Politics of Drug Regulation», en O. O’Donovan y K. Glavanis-Grantham...
Abraham, John (2009): «The Sociological Concomitants of the Pharmaceutical Industry and Medications», en P. Conrad et al. (eds.), American...
Abraham, John y Courtney Davis (2009): «Drug Evaluation and the Permissive Principle: Continuities and Contradictions between Standards and...
Abraham, John y Graham Lewis (1998): «Secrecy and Transparency of Medicines Licensing in the EU», The Lancet, 352: 480-482.
Abraham, John y Graham Lewis (1999): «Harmonising and Competing for Medicines Regulation: How Healthy are the European Union’s System of Drug...
Abraham, John y Tim Reed (2001): «Trading Risks for Markets: The International Harmonization of Pharmaceutical Regulation», Health, Risk &...
Als-Nielsen, Bodil, Wendong Chen, Christian Gluud y Lise L. Kjaergard (2003): «Association of Funding and Conclusions in Randomized Drug Trials:...
Altman, Douglas G. (2002): «Poor-quality Medical Research», Journal of the American Medical Association, 287: 2765-2767.
Angell, Marcia (2000): «Is Academic Medicine for Sale?», New England Journal of Medicine, 342: 1516-1518.
Collins, Harry y Trevor Pinch (2005): Dr. Golem: How to Think about Medicine, Chicago: University of Chicago Press.
Conrad, Peter (1992): “Medicalization and Social Control”, Annual Review of Sociology, Vol. 18: 209-232.
Conrad, Peter (2007): The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders, Baltimore: Johns...
Conrad, Peter (2010): “The social construction of illness: key insights and policy implications”, Journal of Health and Social Behavior, 51(S):...
Conrad, Peter y Kristin K. Barker (2010): «The Social Construction of Illness: Key Insights and Policy Implications», Journal of Health and...
Conrad, Peter y Joseph W. Schneider (1980): Deviance and Medicalization: From Badness to Sickness, St. Louis: Mosby.
Cook, T. D. y D. T. Campbell (1979): Quasi-experimentation: Design and Analysis for Field Settings, Chicago: Rand McNally.
Davis, Courtney y John Abraham (2009): «Deconstructing Pharmaceutical “Science”, “Innovation”, and “Therapeutic Breakthrough”: A case study...
Davis, Courtney y John Abraham (2010): «Rethinking Innovation Accounting in Pharmaceutical Regulation: A case Study in the Deconstruction...
De la Serna, José Luis (2003): «¿Cuál es la tasa de supervivencia con Iressa?», El Mundo Salud, 31 de julio.
Djulbegovic, Benjamín et al. (2000): «The Uncertainty Principle and Industry-sponsored Research», The Lancet, 356, 9248, 23 de diciembre.
Dowie, Mark (2004): «Biotech Critics at Risk. Economics Calls the Shots in the Debate», San Francisco Chronicle, 11 de enero.
Eisenberg, David M., Roger B. Davis, Susan L. Ettner, Scott Appel, Sonja Wilkey, Maria Van Rompay y Ronald C. Kessler (1998): «Trends in Alternative...
FDA (2000a): «FDA Approves Irritable Bowel Sybndrome Treatment for Women», FDA Talk Paper, 9 de febrero.
FDA (2000b): NDA 21-107: Memorandum: Lotronex (alosetron) Safety & Risk Management Summary, Department of Health and Human Services, Center...
FDA (2002a): «Drug Information: Patient-physician Agreement for Lotronex», Center for Drug Evaluation and Research, 7 de junio.
FDA (2002b): FDA Advisoty Committee Meeting Briefi ng Document NDA 21-399 for the use of IRESSA for the treatment of patients with locally...
FDA (2002c): Oncologic Drugs Advisory Committee, 72nd Meeting http://www.fda.gov/ohrms/dockets/ ac/02/transcripts/3894T.htm
FDA (2003a): «Questions and Answers on Iressa», www.dsa.gov/drug/infopage/iressa/iressaQ&A. htm
FDA (2003b): «FDA Approves New Type of Drug for Lung Cancer», Press Release de la FDA, 5 de mayo, www.fda.gov/bbs/topics/NEWS/2003/ NEW00901.html
Feuerstein, Adam (2002a): «After Iressa, Investors Embrace Gentler FDA», The Street.com (en línea). http://www.thestreet.com/_yahoo/tech/adamfeuerstein/10044154.html,...
Feuerstein, Adam (2002b): «AstraZeneca Scores Come back Victory on Iressa», The Street.com (en línea). http://www. thestreet .com/_yahoo/tech/adamfeuerstein/10044113.html,...
Stolley, Paul D. (2002): «Statement», Testimony before FDA Gastrointestinal Drugs and Drug Safety Advisory Committee Hearing concerning Alosetron,...
Surman, Craig BruceHackett, Michael C. Monuteaux, Carter R. Petty, Stephen V. Faraone, Thomas J. Spencer, Nicole F. Chu y Joseph Biederman...
Suzuki, Toshihiro (2003): «Petition for inmediate cessation of all sales of Iressa and subsequent revocation of Ministry of Health, Labor...
The Lancet (2001): «The Tightening Grip of Big Pharma», The Lancet, 357, 9263: 1141.
The Lancet (2002): «The FDA and The Lancet: an exchange», The Lancet, 358, 9279: 415-418.
Tingey, R. C., M. J. Lambert, G. M. Burlingame y N. B. Hansen (1996): «Assesing Clinical Signifi cance: Proposed Extensions to Method», Psychotherapy...
Turner, Bryant S. (1995): Medical power and social knowledge, Londres: Sage Publications.
Wallis, Roy (1979): On the Margins of Science: The Social Construction of Rejected Knowledge, Sociological Review Monographs, 27, Stafford:...
Warde, Ibrahim (2001): «Confl icts of Interest in the Campus. For Sale: US Academic Integrity», Le Monde Diplomatique, 1 de marzo.
Wazana, A. (2000): «Physicians and the Pharmaceutical Industry: Is a Gift ever just a Gift?», Journal of the American Medical Association,...
Westen, Drew I. (2005): «Patients and Treatments in Clinical Trials are not Adequately Representative of Clinical Practice», en Norcross,...
Will, Catherine M. (2007): «The Alchemy of Clinical Trials», BioSocieties, 2 (1): 85-99.
Willman, David (2000a): «The Rise and Fall of the Killer Drug Razulin», Life Extension Magazine, septiembre.
Willman, David (2000b): «FDA Minimized Issue of Lotronex’s Safety», Los Angeles Times, 16 de noviembre.
Willman, David (2000c): «Drug Lotronex Pull over for Safety Fears», Los Angeles Times, 29 de noviembre.
Willman, David (2000d): «How a New Policy Led to Seven Dead ly Drugs», Los Angeles Times, 20 de diciembre.
Willman, David (2000e): «Lotronex: Officer Foresaw Deadly Effects», Los Angeles Times, 20 de diciembre.
Wilmshurt, Peter (1997): «The Politics of Disclosure», The Lancet, 349 (9064): 1558.
Wilmshurt, Peter (2000): «Academia and industry», The Lancet, 356, 9226: 338-339.
Wolfe, Sidney M. (2002): «Benefits of Alosetron: serious problem with Irritable Bowel Syndrome studies because very high placebo response...
Wolfe, Sidney M., Elizabeth Barbehenn y Larry Sasich (2000): «Letter to the Food and Drug Administration Updating the number of cases of ischemic...
Wright, James R., Sarah Bouma, Ian Dayes, Jonathan Sussman, Marko R. Simunovic, Mark N. Levine y Tim J. Whelan (2006): «The importance of...
Zimmerman, Mark, Jill I. Mattia y Michael A. Posternak (2002): «Are Subjects in Pharmacological Treatment Trials of Depression Representative...
Zola, Irving Kenneth (1972): «Medicine as an Institution of Social Control», The Sociological Review, 20 (4): 487-509.